CANDEL THERAPEUTICS, INC. Investment Income, Interest
CANDEL THERAPEUTICS, INC. (CADL) reported Investment Income, Interest of $240.00 thousand for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-13.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2024-08-13
- CANDEL THERAPEUTICS, INC. investment income, interest for the quarter ending 2024-06-30 was $240.00K, a 47.02% decline year-over-year.
- CANDEL THERAPEUTICS, INC. investment income, interest for the quarter ending 2024-03-31 was $320.00K, a 54.99% decline year-over-year.
- CANDEL THERAPEUTICS, INC. investment income, interest for the quarter ending 2023-12-31 was $415.00K, a 48.38% decline year-over-year.
- CANDEL THERAPEUTICS, INC. investment income, interest for the quarter ending 2023-09-30 was $502.00K, a 46.36% increase year-over-year.
- CANDEL THERAPEUTICS, INC. investment income, interest for fiscal 2023 was $2.08M, a 70.85% increase from fiscal 2022.
- CANDEL THERAPEUTICS, INC. investment income, interest for fiscal 2022 was $1.22M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2024-06-30 | $240.00K 10-Q · filed 2024-08-13 | $560.00K 10-Q · filed 2024-08-13 | $975.00K derived: sum of 3 quarters · filed 2024-08-13 | $1.48M derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | $320.00K 10-Q · filed 2024-05-14 | $735.00K derived: sum of 2 quarters · filed 2024-05-14 | $1.24M derived: sum of 3 quarters · filed 2024-05-14 | $1.69M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-12-31 | $415.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $917.00K derived: sum of 2 quarters · filed 2024-03-28 | $1.37M derived: sum of 3 quarters · filed 2024-08-13 | $2.08M 10-K · filed 2024-03-28 |
| 2023-09-30 | $502.00K 10-Q · filed 2023-11-09 | $955.00K derived: sum of 2 quarters · filed 2024-08-13 | $1.67M 10-Q · filed 2023-11-09 | $2.47M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-06-30 | $453.00K 10-Q · filed 2024-08-13 | $1.16M 10-Q · filed 2024-08-13 | $1.97M derived: sum of 3 quarters · filed 2024-08-13 | $2.31M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $711.00K 10-Q · filed 2024-05-14 | $1.51M derived: sum of 2 quarters · filed 2024-05-14 | $1.86M derived: sum of 3 quarters · filed 2024-05-14 | $1.93M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $804.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $1.15M derived: sum of 2 quarters · filed 2024-03-28 | $1.22M derived: sum of 3 quarters · filed 2024-03-28 | $1.22M 10-K · filed 2024-03-28 |
| 2022-09-30 | $343.00K 10-Q · filed 2023-11-09 | $413.00K derived: sum of 2 quarters · filed 2023-11-09 | $414.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $70.00K 10-Q · filed 2023-08-10 | $71.00K 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |